VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Henan Cancer Hospital
Send
Updated on 5 August 2020
See if I qualify
cyclophosphamide
prednisone
rituximab
lymphoma
bortezomib
epirubicin
marginal zone lymphoma
malt

Summary

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

Description

Marginal zone lymphoma (MZL) is a relatively common group of non-Hodgkin's lymphoma (NHL). The incidence rate is only inferior to diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Currently, NCCN guidelines recommend same treatment plan of FL like R-CHOP as the primary treatment for MZL. However, due to the great difference in cell origin and biological characteristics between FL and MZL, some patients can not achieve complete remission or relapse quickly after standard first-line treatment. A number of phase II clinical studies have evaluated the good efficacy of rituximab combined with chemotherapy in the treatment of MZL. Previous studies have shown that NF-B signaling pathway is in abnormal activation state in MZL. Velcade(Bortezomib), a proteasome inhibitor targeting NF-B pathway, has a promising therapeutic prospect in relapsed and refractory MZL. The goal of our trial is to assess the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

Details
Condition MALT Lymphoma, marginal zone lymphoma, marginal zone lymphoma
Age 18years - 70years
Treatment Cyclophosphamide, Rituximab, Epirubicin, Prednisone, Velcade
Clinical Study IdentifierNCT04433156
SponsorHenan Cancer Hospital
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age between 18 to 70 years old (including 18 and 70)
Diagnosed as marginal zone lymphoma
No receiving chemotherapy before enrollment
Indications for treatment: 1) symptoms related to tumor; 2) end-organ function damage
large mass; 4) continuous or rapid progress of disease; 5) patient's willingness
Having at least one measurable lesions
World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 0-1
Life expectancy no less than 3 months
enough main organ function
Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study
Agreeing to sign the written informed consents

Exclusion Criteria

Diagnosed as central nervous system lymphoma
World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 2
Other malignant tumor history or active malignant tumor need be treated
Serious surgery and trauma less than two weeks
Systemic therapy for serious acute/chronic infection
Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months
Active tuberculosis. Patients suspected of active TB need to be examined for chest X-ray, sputum and clinical symptoms and signs
HIV-positive, AIDS patients and untreated active hepatitisHBV/HBV and HCV
Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months
Patients with a history of mental illness
Researchers determine unsuited to participate in this trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cyclophosphamide
prednisone
rituximab
lymphoma
bortezomib
epirubicin
marginal zone lymphoma
malt

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.